NCT04233814View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetic Study of LTI-03 in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

January 20, 2020

Primary Completion Date

December 23, 2021

Study Completion Date

December 23, 2021

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03)

LTI-03, a Caveolin-1 scaffold protein-derived 7-amino acid peptide to be administered as a dry powder by inhalation through a dry powder inhaler.

DRUG

Placebo

Matching placebo is micronized lactose powder administered by inhalation through a dry powder inhaler.

Trial Locations (1)

BT9 6AD

Celerion, Belfast

Sponsors

Lead Sponsor

Rein Therapeutics
All Listed Sponsors
lead

Rein Therapeutics

INDUSTRY

NCT04233814 - Safety, Tolerability and Pharmacokinetic Study of LTI-03 in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter